Stoke Therapeutics, Inc. (STOK) Misses Q2 EPS by 6c
Get Alerts STOK Hot Sheet
Join SI Premium – FREE
Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q2 EPS of ($0.69), $0.06 worse than the analyst estimate of ($0.63).
For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share